Hepatitis C Antibody Test · Blood

Hepatitis C can live in your body for 20 or 30 years without causing a single symptom you would notice. By the time you feel something wrong, the virus may have already scarred your liver badly enough to cause cirrhosis or liver cancer. The good news: a simple blood test can find it, and modern treatments cure more than 95% of infections in as little as 8 weeks. The question is whether you have ever been tested.

Anti-HCV (hepatitis C virus antibody) is the standard first step for finding out. If your immune system has ever encountered the hepatitis C virus, it produces antibodies against it. This test detects those antibodies. A positive result does not automatically mean you have an active infection right now, but it does mean your body has seen the virus, and you need a follow-up test to determine what happens next.

What This Test Actually Tells You

Anti-HCV is a qualitative screening test. The result is either reactive (positive) or non-reactive (negative). It does not measure a number on a sliding scale like cholesterol or blood sugar. It answers one question: has your immune system ever produced antibodies against the hepatitis C virus?

A positive result means your body was exposed to the virus at some point. It does not tell you whether the virus is still actively replicating in your body. Among people who test anti-HCV positive, a substantial fraction have already cleared the virus, either spontaneously or through prior treatment. In one large Spanish population study, about 74% of anti-HCV positive individuals no longer had active infection. In an English antenatal screening program, only about 52% of anti-HCV positive women had detectable virus. The critical next step after a positive antibody result is an HCV RNA test (also called a viral load or nucleic acid test), which detects the virus itself.

A negative result usually means you have never been infected. But there are exceptions. In the first few months after exposure, your body may not have produced enough antibodies yet for the test to detect them. In one study of HIV-positive men with acute hepatitis C, 75% were antibody-negative at the time their virus was first detected by RNA testing. About 5% remained antibody-negative even after a full year. If you have a recent high-risk exposure and a negative antibody test, an RNA test can catch what the antibody test misses.

Liver Disease and Cirrhosis

Chronic hepatitis C is one of the leading causes of serious liver disease worldwide. In a study of volunteer blood donors who tested anti-HCV positive, 85% had detectable virus in their blood and 90% had chronic hepatitis visible on liver biopsy. Even those with completely normal liver enzyme levels (ALT) could have significant underlying liver damage.

The virus causes slow, progressive scarring of the liver over decades. Left untreated, chronic hepatitis C can lead to cirrhosis, liver failure, and the need for a transplant. In the R.E.V.E.A.L.-HCV study, a community-based cohort of nearly 24,000 adults in Taiwan followed for an average of 16.2 years, people who were anti-HCV positive had roughly 12 times the risk of dying from liver disease compared to those who were negative (adjusted hazard ratio 12.48). Among anti-HCV positive individuals with detectable virus in their blood, the risk was even higher than in those who had cleared the virus.

Heart Disease and Stroke

Hepatitis C is not just a liver disease. The virus drives chronic inflammation throughout the body, and that inflammation appears to affect blood vessels. A meta-analysis of 22 observational studies found that people with HCV infection had about 65% higher risk of dying from cardiovascular causes compared to uninfected individuals (pooled odds ratio 1.65). The risk of having visible plaque in the carotid arteries, the blood vessels that supply the brain, was more than doubled (odds ratio 2.27).

The cardiovascular risk was even more pronounced in people who also had diabetes or high blood pressure, where the odds of a heart attack or stroke were about 71% higher than in uninfected people with those same conditions. In the R.E.V.E.A.L.-HCV cohort, anti-HCV positive individuals had about 50% higher circulatory disease mortality (hazard ratio 1.50) after adjusting for age, sex, and lifestyle factors.

Kidney Disease, Cancer, and Overall Mortality

The same Taiwanese community cohort showed that hepatitis C reaches well beyond the liver. Anti-HCV positive individuals had nearly triple the risk of dying from kidney disease (hazard ratio 2.77 for nephritis and related conditions) and significantly higher mortality from several cancers, including esophageal cancer (hazard ratio 4.08) and thyroid cancer (hazard ratio 8.22). All-cause mortality was nearly double that of uninfected individuals (hazard ratio 1.89).

These risks were concentrated in people with active viral replication. Anti-HCV positive individuals whose virus had cleared (RNA-negative) had substantially lower risk than those with ongoing infection, reinforcing why confirming active infection through RNA testing matters so much.

Curing Hepatitis C Changes the Trajectory

Modern antiviral treatment does not just eliminate the virus. It changes your risk profile for years afterward. In a prospective study of 1,323 people with hepatitis C and compensated cirrhosis, achieving a sustained virologic response (SVR, meaning the virus remains undetectable 12 weeks after finishing treatment, which is considered a cure) was associated with a 71% reduction in liver cancer risk, a 74% reduction in liver decompensation, a 58% reduction in cardiovascular events, and a 73% reduction in overall mortality compared to those who were not cured.

A large US insurance database study of over 245,000 adults with chronic hepatitis C found that those treated with direct-acting antivirals had 57% lower all-cause mortality, 64% lower risk of liver decompensation, and meaningful reductions in new diabetes and chronic kidney disease compared to untreated individuals. Even non-liver outcomes improved, suggesting that the systemic inflammation driven by the virus has widespread consequences that treatment can reverse.

Who Should Be Tested

In 2020, both the CDC and the U.S. Preventive Services Task Force (USPSTF) updated their recommendations to call for universal hepatitis C screening: every adult aged 18 to 79 should be tested at least once in their lifetime. This was a major shift from earlier guidance that targeted only people born between 1945 and 1965 or those with known risk factors like injection drug use.

The reason for universal screening is straightforward. Risk-based testing misses too many people. In a large US primary care study of over 209,000 adults, more than 80% of anti-HCV positive patients had never been identified under risk-based screening. Many people with hepatitis C have no identifiable risk factor, or they have risk factors they do not disclose. Universal one-time screening is cost-effective in populations where anti-HCV prevalence exceeds just 0.07%, a threshold met in essentially every adult population studied.

• Everyone aged 18 to 79: should be tested at least once, regardless of risk factors.
• People who inject or have ever injected drugs: should be tested and retested periodically while risk continues.
• Anyone who received a blood transfusion or organ transplant before 1992: screening was not yet available for donated blood.
• People on long-term hemodialysis: hepatitis C prevalence is significantly higher in this group.
• People living with HIV: co-infection is common and antibody testing can be less reliable, so RNA testing may also be warranted.
• Pregnant women: CDC recommends screening during each pregnancy.

How to Read Your Result

Because anti-HCV is a qualitative test, there are no graded reference ranges like you would see for cholesterol or blood sugar. Your result will be reported as reactive or non-reactive. Some labs also report a signal-to-cutoff (S/CO) ratio, which reflects the strength of the antibody signal. A higher S/CO generally makes a true positive more likely, but the clinical action is the same: any reactive result needs confirmatory HCV RNA testing.

One research study found that among anti-HCV positive results with a low signal-to-cutoff ratio (below about 3.7 on one common assay), 86% turned out to be false positives with no detectable virus and no confirmatory antibody. Only 11% of those low-positive results had actual viral RNA. This is why confirmatory testing is not optional after a positive screen.

When Results Can Be Misleading

Anti-HCV is a stable marker. Unlike many blood tests, it is not meaningfully affected by fasting, time of day, recent meals, exercise, or common medications like statins, metformin, or blood pressure drugs. The main sources of misleading results are biological, not logistical.

• False positives in low-risk populations: When the background prevalence of hepatitis C is low (such as general antenatal screening), a large proportion of reactive antibody results will be false positives. This is a mathematical property of any screening test, not a flaw in the assay. Confirmatory RNA testing resolves this.
• Window period in early infection: After initial exposure, it can take an average of 15 to 22 weeks before antibodies become detectable. During this window, the antibody test will be negative even though the virus is actively replicating. If you suspect a recent exposure, an HCV RNA test can detect infection weeks before antibodies appear.
• Immunosuppression: People with severely weakened immune systems, particularly those with advanced HIV, may fail to produce detectable antibodies despite active hepatitis C infection. In one study of HIV-positive men, 5% remained anti-HCV negative more than a year after confirmed viral infection. If you are immunosuppressed and at risk, HCV RNA testing is more reliable than antibody testing alone.
• Persistent positivity after cure: Anti-HCV antibodies typically remain positive for life, even after the virus has been completely eliminated by treatment. A positive antibody test in someone who was previously treated and cured does not mean reinfection. Only an HCV RNA test can determine whether the virus has returned.

Tracking Over Time

Unlike continuous biomarkers such as cholesterol or blood sugar, anti-HCV does not require serial tracking in the traditional sense. The antibody result is essentially permanent: once positive, it stays positive. The value of repeat testing comes in specific situations.

If your initial test is negative and you have no ongoing risk factors, a single lifetime screen is sufficient. If you continue to engage in activities that could expose you to hepatitis C (such as injection drug use), periodic retesting is recommended because a new infection acquired after your last negative test would not be detected without retesting. After successful treatment, the test to track is HCV RNA, not anti-HCV. Your antibody will remain positive, but your RNA should remain undetectable. Most clinicians check RNA at 12 weeks post-treatment to confirm cure, with occasional follow-up if reinfection risk is ongoing.

What to Do With an Abnormal Result

If your anti-HCV comes back reactive, the immediate next step is an HCV RNA test. Many labs offer reflex testing, where a reactive antibody automatically triggers an RNA test on the same blood sample, so you do not need a second draw. If your lab does not do this automatically, request it.

If RNA is positive (confirming active infection), the standard workup includes liver function tests (ALT, AST), a non-invasive assessment of liver scarring (such as FibroScan or the FIB-4 score calculated from routine blood tests), hepatitis B testing (to check for co-infection before treatment), and kidney function testing. A hepatologist or infectious disease specialist can guide treatment selection, though many primary care physicians now prescribe direct-acting antivirals directly. Treatment courses are typically 8 to 12 weeks of a once-daily oral pill, with cure rates above 95%.

If RNA is negative (meaning the virus is no longer active), no treatment is needed. You either cleared the infection on your own or were treated successfully in the past. Your antibody will remain positive on future tests, which is normal and does not indicate a problem. Keep a record of your RNA-negative result so you can provide it if a future provider sees the positive antibody and raises concerns.